All In Biotech

Drug Trial Radar · NCT06452433

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Gumarontinib Combined With Third-generation EGFR-TKI in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Amplification Following EGFR-TKI Treatment Failure.

Last checked: Nov 20, 2026Latest source record: Jun 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

91

Planned (sponsor's estimate)

Start

Jun 1, 2024

Primary completion

Dec 12, 2027

Study completion Feb 2, 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the efficacy and safety of gumarontinib combined with third-generation EGFR-TKI in the treatment of locally advanced or metastatic NSCLC with MET amplification after first-line EGFR-TKI failure, without limiting the type of third-generation EGFR-TKI. The study was divided into 2 cohorts: Cohort 1 included patients with MET amplification after third-generation EGFR-TKI first-line therapy resistance, and cohort 2 included patients with MET amplification after first-generation EGFR-TKI first-line therapy resistance.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • gumarontinibDrug

    300 mg , qd ,po, expect 6 months.

  • third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)Drug

    According to the actual situation of patients. Take as recommended, expect 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: From initial medication to the date of first documented progression or end of medication. Assessed up to 6 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.